Cue Biopharma (CUE) Stock Price, News & Analysis

Company Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $0.78 to $0.81
• 50-Day Range: $0.65 to $0.91
• 52-Week Range: $0.45 to $1.99
• Volume: 76,974 shs
• Average Volume: 253,622 shs
• Market Capitalization: $60.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cue Biopharma Stock Analysis - MarketRank™

Cue Biopharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 543rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cue Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cue Biopharma is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cue Biopharma is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cue Biopharma has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.28% of the float of Cue Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cue Biopharma has recently decreased by 22.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cue Biopharma does not currently pay a dividend.

Dividend Growth

Cue Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.58

Percentage of Shares Shorted

1.28% of the float of Cue Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Cue Biopharma has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cue Biopharma has recently decreased by 22.24%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.43

News Sentiment

Cue Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cue Biopharma this week, compared to 1 article on an average week.

Search Interest

5 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

1 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cue Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.78% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.04% of the stock of Cue Biopharma is held by institutions.

CUE Stock Analysis - Frequently Asked Questions

How have CUE shares performed this year?

Cue Biopharma's stock was trading at $1.09 at the beginning of 2025. Since then, CUE shares have decreased by 27.2% and is now trading at $0.7940.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. The company had revenue of $2.95 million for the quarter, compared to analysts' expectations of $2 million. Cue Biopharma had a negative net margin of 469.35% and a negative trailing twelve-month return on equity of 230.13%.

Who are Cue Biopharma's major shareholders?

Top institutional investors of Cue Biopharma include GC Wealth Management RIA LLC (4.42%), Angeles Wealth Management LLC (0.16%), Northwestern Mutual Wealth Management Co. (0.11%) and Group One Trading LLC. Insiders that own company stock include Daniel R Passeri, Anish Suri and Peter A Kiener.
View institutional ownership trends.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CUE
• CIK: 1645460
• Web: www.cuebiopharma.com
• Phone: (617) 949-2680
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.67 million
• Net Margins: -469.35%
• Pretax Margin: -469.35%
• Return on Equity: -230.13%
• Return on Assets: -111.16%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.60
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $9.29 million
• Price / Sales: 6.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: 3.31

Miscellaneous

• Outstanding Shares: 76,850,000
• Free Float: 68,562,000
• Market Cap: $61.02 million
• Optionable: Optionable
• Beta: 1.53